EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia

Dora Čerina Pavlinović iD, Natalija Dedić Plavetić iD, Ingrid Belac Lovasić iD, Robert Šeparović iD, Josipa Flam iD, Marija Pancirov iD, Žarko Bajić iD, Snježana Tomić iD, Eduard Vrdoljak iD

The Breast Journal · 2024

DOI: 10.1155/2024/5648845 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Breast Journal, 2024. Verfasst von Dora Čerina Pavlinović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology University Hospital Center Split School of Medicine University of Split, Split, Croatia. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Disease recurrence in patients with the early hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) breast tumor subtype is particularly challenging to manage due to its complex and very heterogeneous biological nature. Namely, due to primary and secondary resistance, one‐quarter of patients with early‐stage disease will experience disease recurrence. This variability in the timing of recurrence highlights the need to better identify key biomarkers that could predict therapeutic outcomes and guide personalized treatment strategies for these patients. Mutations in the phosphatidylinositol 4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA) gene are highly prevalent (30–40%) in HR+/HER2− advanced breast cancer. They lead to activation of the PI3K/AKT/mTOR pathway, promoting cell growth, and proliferation, and are associated with poor prognosis in advanced breast cancer. Our aim was to examine the association between and impact of PIK3CA mutation status on disease‐free survival (DFS) in HR+/HER2− early breast cancer patients.

Methods

This cohort study was multicentric and retrospective in nature and was conducted at five Croatian institutions from July 2020 to December 2021. The study included initially early and locally advanced operable HR+/HER2− breast cancer patients who were diagnosed with disease recurrence during adjuvant hormonal treatment or within the first six years of follow‐up.

Results

A total of 186 patients were included, 40.9% of whom tested positive for the PIK3CA mutation. Primary and adjuvant treatment, particularly adjuvant endocrine treatment, were similar between the two groups. After adjustment for 14 relevant covariates, we found that patients with a positive PIK3CA status and the H1047 PIK3CA mutation had a significantly lower hazard of disease recurrence than patients with no PIK3CA mutation (HR 0.65; 95% CI 0.45; 0.95; p = 0.024; false discovery rate, FDR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationHumansFemaleMiddle AgedRetrospective StudiesDisease-Free SurvivalCroatiaAdultChemotherapy, AdjuvantReceptors, ProgesteroneAgedReceptors, EstrogenAntineoplastic Agents, HormonalNeoplasm Recurrence, LocalBiomarkers, Tumor

Substanzen

Class I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenAntineoplastic Agents, HormonalBiomarkers, TumorPIK3CA protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology University Hospital Center Split School of Medicine University of Split, Split, Croatia.
  • Department of Oncology University Hospital Center Zagreb School of Medicine University of Zagreb, Zagreb, Croatia.
  • School of Medicine University of Rijeka, Rijeka, Croatia.
  • Department of Medical Oncology Sestre Milosrdnice University Hospital Centre University Hospital for Tumors, Zagreb, Croatia.
  • Department of Radiotherapy and Oncology University Hospital Center Osijek School of Medicine University of Osijek, Osijek, Croatia.
  • Research Unit "Dr. Mirko Grmek" Psychiatric Clinic "Sveti Ivan", Zagreb, Croatia.

ORCID-Profile: Dora Čerina Pavlinović, Natalija Dedić Plavetić, Ingrid Belac Lovasić, Robert Šeparović, Josipa Flam, Marija Pancirov, Žarko Bajić, Snježana Tomić, Eduard Vrdoljak

Förderung

  • Novartis

Zitieren

APA

Čerina Pavlinović, D., Dedić Plavetić, N., Belac Lovasić, I., Šeparović, R., Flam, J., Pancirov, M., Bajić, Ž., Tomić, S., & Vrdoljak, E. (2024). Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia. The Breast Journal. https://doi.org/10.1155/2024/5648845

Vancouver

Čerina Pavlinović D, Dedić Plavetić N, Belac Lovasić I, Šeparović R, Flam J, Pancirov M, et al. Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia. The Breast Journal. 2024. doi:10.1155/2024/5648845

BibTeX
@article{erinaPavlinovi2024,
  author = {Čerina Pavlinović, Dora and Dedić Plavetić, Natalija and Belac Lovasić, Ingrid and Šeparović, Robert and Flam, Josipa and Pancirov, Marija and Bajić, Žarko and Tomić, Snježana and Vrdoljak, Eduard},
  title = {Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia},
  journal = {The Breast Journal},
  year = {2024},
  doi = {10.1155/2024/5648845}
}
Kostenlos starten →